Cardiovascular diseases remain a leading cause of mortality worldwide, necessitating novel approaches to address the underlying genetic/epigenetic factors. Advancements in genome/epigenome targeting strategies, coupled with innovative delivery methods, have revolutionized the field of cardiology research and treatment. This transformative technology allows for precise modification of genetic as well as epigenetic material associated with cardiovascular diseases, offering the potential to correct anomalies, enhance therapeutic outcomes, and even promote cardiac function. Gene targeting strategies have demonstrated immense promise in pre-clinical studies, but the translation of these methods to clinical practice requires a comprehensive understanding of their mechanisms, delivery efficiency, and safety.
This research proposal aims to investigate, develop, and refine genome/ epigenome editing and targeting techniques, alongside optimizing their delivery systems, to accelerate progress in the field of cardiology research and clinical interventions. We will investigate the efficiency, specificity, and safety of various gene-editing tools such as CRISPR/Cas9 and explore novel targeting approaches tailored to cardiovascular diseases. In the same time, we will evaluate advanced delivery systems, including nanoparticle-based vectors and AAV (Adeno-associated virus) technologies, to improve the precision and effectiveness of genetic modifications. Through this work, we seek to provide a foundation for translating these technologies from the laboratory to the clinic, offering potential therapeutic solutions for inherited cardiovascular conditions and heart diseases.
This research project will encompass a comprehensive exploration of gene editing and targeting strategies in the context of cardiology, with a particular emphasis on addressing the challenges of off-target effects, gene delivery specificity, and efficiency. The scope of this study will encompass several key areas: genome/epigenome editing, gene delivery systems, safety and clinical translation. We welcome both comprehensive review articles and original research contributions.
Keywords:
Gene editing, gene targeting, CRISPR/Cas, cardiovascular research, AAV, Lipid nanoparticles, gene therapy, gene delivery, molecular medicine, clinical applications
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Cardiovascular diseases remain a leading cause of mortality worldwide, necessitating novel approaches to address the underlying genetic/epigenetic factors. Advancements in genome/epigenome targeting strategies, coupled with innovative delivery methods, have revolutionized the field of cardiology research and treatment. This transformative technology allows for precise modification of genetic as well as epigenetic material associated with cardiovascular diseases, offering the potential to correct anomalies, enhance therapeutic outcomes, and even promote cardiac function. Gene targeting strategies have demonstrated immense promise in pre-clinical studies, but the translation of these methods to clinical practice requires a comprehensive understanding of their mechanisms, delivery efficiency, and safety.
This research proposal aims to investigate, develop, and refine genome/ epigenome editing and targeting techniques, alongside optimizing their delivery systems, to accelerate progress in the field of cardiology research and clinical interventions. We will investigate the efficiency, specificity, and safety of various gene-editing tools such as CRISPR/Cas9 and explore novel targeting approaches tailored to cardiovascular diseases. In the same time, we will evaluate advanced delivery systems, including nanoparticle-based vectors and AAV (Adeno-associated virus) technologies, to improve the precision and effectiveness of genetic modifications. Through this work, we seek to provide a foundation for translating these technologies from the laboratory to the clinic, offering potential therapeutic solutions for inherited cardiovascular conditions and heart diseases.
This research project will encompass a comprehensive exploration of gene editing and targeting strategies in the context of cardiology, with a particular emphasis on addressing the challenges of off-target effects, gene delivery specificity, and efficiency. The scope of this study will encompass several key areas: genome/epigenome editing, gene delivery systems, safety and clinical translation. We welcome both comprehensive review articles and original research contributions.
Keywords:
Gene editing, gene targeting, CRISPR/Cas, cardiovascular research, AAV, Lipid nanoparticles, gene therapy, gene delivery, molecular medicine, clinical applications
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.